GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (OTCPK:MLLNF) » Definitions » Debt-to-EBITDA

Malin (MLLNF) Debt-to-EBITDA : 0.00 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Malin Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Malin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Malin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Malin's annualized EBITDA for the quarter that ended in Jun. 2024 was $0.22 Mil. Malin's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Malin's Debt-to-EBITDA or its related term are showing as below:

MLLNF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.71   Med: 0.01   Max: 36.63
Current: -0.11

During the past 9 years, the highest Debt-to-EBITDA Ratio of Malin was 36.63. The lowest was -1.71. And the median was 0.01.

MLLNF's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs MLLNF: -0.11

Malin Debt-to-EBITDA Historical Data

The historical data trend for Malin's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Debt-to-EBITDA Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 36.63 0.57 0.07 0.01 0.25

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.05 -

Competitive Comparison of Malin's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malin's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Malin's Debt-to-EBITDA falls into.



Malin Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Malin's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.109 + 0) / 0.436
=0.25

Malin's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Malin  (OTCPK:MLLNF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Malin Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Malin's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Malin Business Description

Traded in Other Exchanges
Address
50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a global life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where they believe innovative life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines